Search hospitals
>
Georgia
>
Atlanta
Emory University Hospital/Winship Cancer Institute
Claim this profile
Atlanta, Georgia 30322
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Multiple Myeloma
Conducts research for Pancreatic Cancer
1082 reported clinical trials
100 medical researchers
Summary
Emory University Hospital/Winship Cancer Institute is a medical facility located in Atlanta, Georgia. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Multiple Myeloma, Pancreatic Cancer and other specialties. Emory University Hospital/Winship Cancer Institute is involved with conducting 1,082 clinical trials across 817 conditions. There are 100 research doctors associated with this hospital, such as Jonathan Cohen, MD, Ticiana A. Leal, Conor Steuer, and Olatunji Alese.
Area of expertise
Cancer
Emory University Hospital/Winship Cancer Institute has run 163 trials for Cancer. Some of their research focus areas include:
Breast Cancer
Emory University Hospital/Winship Cancer Institute has run 144 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Jonathan Cohen, MD
Jadestone Clinical Research, LLC
1 year of reported clinical research
Ticiana A. Leal
University of Wisconsin Hospital and Clinics
5 years of reported clinical research
Conor Steuer
Emory University Hospital Midtown
1 year of reported clinical research
Olatunji Alese
Emory University Hospital/Winship Cancer Institute
8 years of reported clinical research
Clinical Trials running at Emory University Hospital/Winship Cancer Institute
Lung Cancer
Breast Cancer
Prostate Cancer
Skin Cancer
Breast cancer
Multiple Myeloma
Ovarian Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting
2 awards
Phase 3
12 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Emory University Hospital/Winship Cancer Institute?
Emory University Hospital/Winship Cancer Institute is a medical facility located in Atlanta, Georgia. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Multiple Myeloma, Pancreatic Cancer and other specialties. Emory University Hospital/Winship Cancer Institute is involved with conducting 1,082 clinical trials across 817 conditions. There are 100 research doctors associated with this hospital, such as Jonathan Cohen, MD, Ticiana A. Leal, Conor Steuer, and Olatunji Alese.
Where is Emory University Hospital/Winship Cancer Institute located?
**Emory Winship Cancer Institute Location and Parking Information:** - **Address:** 1365 Clifton Road NE, Building B, Atlanta, Georgia, on the Emory University Hospital campus. - **Directions:** From I-85, take the North Avenue exit (Exit #249D), turn left on North Avenue, right onto Peachtree Street, and then right into the Visitor Parking Deck after passing Linden Avenue. - **Parking:** Valet parking and drop-off at 36 Linden Avenue NE. Onsite self-parking at 575 W Peachtree Street NW.
Who should I call to ask about financial aid or insurance network?
**Emory University Hospital/Winship Cancer Institute Financial Assistance:** - For financial assistance, including insurance coverage, out-of-pocket obligations, and locating financial coverage options, contact a Financial Counselor at (404) 778-7318. - For insurance department inquiries or general billing questions, call (404) 727-7551 and press 2.
What insurance does Emory University Hospital/Winship Cancer Institute accept?
Emory University Hospital/Winship Cancer Institute accepts most major insurance plans, including private and employer-based plans, Federal health insurance marketplace plans, traditional Medicare, and Medicare Advantage plans. They will file your insurance claims, both primary and secondary, and offer the services of a Financial Counselor, free of charge, to assist with the financial aspects of cancer treatment. For insurance or billing questions, please call (404) 778-7318, and for more information on accepted insurance plans, contact 404-778-7777 or 1-800-75-EMORY (1-800-753-6679).
What awards or recognition has Emory University Hospital/Winship Cancer Institute received?
Emory University Hospital and Winship Cancer Institute boast Magnet® recognition from the American Nurses Credentialing Center (ANCC), highlighting their excellence in nursing professionalism, teamwork, and patient care. The Emory University School of Medicine is renowned for its significant contributions to medical research, including Dr. Byron Au-Yeung's studies on T cell diversity and Dr. Cassandra Quave's ethnobotany research focusing on antibiotic properties.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.